( CAMBRIDGE Mass.--(BUSINESS WIRE)--Mar ...)CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone,Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced preliminary results of a phase 2 clinical trial studying CRx-139 (a synergistic combination of 3mg prednisolone and the antidepressant paroxetine) and 3mg prednisolone alone, in patients with rheumatoid arthritis (RA). This trial served two important purposes. One purpose was to determine the effect of 3mg of prednisolone alone (a very low dose) in RA and to contrast this effect with the activity previously reported with CRx-102, a synergistic combination of very low dose prednisolone and dipyridamole. The results with 3mg prednisolone confirm that the anti-inflammatory benefits previously observed in three phase 2a clinical trials with CRx-102 are due to the synergistic activity of CRx-102's components, as opposed to an effect derived from the prednisolone component alone. Another purpose of the trial was to evaluate the activity of CRx-139 vs. prednisolone alone. CRx-139 did not show statistical significance on the primary endpoint of the trial. CRx-139 did show statistical significance on multiple other endpoints, requiring further analysis.

CRx-102 Confirmed as Superior to Prednisolone Alone and Advances on Plan in RA and OA

Comparison of treatment outcomes for CRx-102 (from previously reported results in RA) versus very low dose prednisolone alone (from the study reported here) shows that CRx-102 is superior to the 3mg of prednisolone alone. Importantly, subjects in the two studies had the same demographics and similar baseline disease status, allowing for comparison of study results. The following table summarizes the ACR 20 scores for CRx-102 and low dose prednisolone, respectively, at 6 weeks, the duration of the CRx-102 RA study. -0-

Trial                              Regimen       Patients   Patients

                                                  Achieving  Achieving

       
'"/>




Page: 1 2 3 4 5 6 
Related medicine technology :

1. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and
Pain, but Not CRP
2. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139
Presented at EULAR
3. Novel Mechanism Insights and Additional Data on CombinatoRx Drug
Candidates to Be Presented at Upcoming EULAR Meeting
4. CombinatoRx to Present Combination High Throughput Screening (cHTS)
Data at Upcoming AACR Meeting
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types
6. XTL Provides Update on Phase I Clinical Trial of XTL-2125
7. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides
Sustained Immune Response in 100 Percent of Women up to 55 Years of
Age
8. Daytrana (methylphenidate transdermal system) Provides Significant
Effectiveness in ADHD Symptom Relief in Both Boys and Girls
9. DURECT Provides an Update to the Memryte Program Under Development
by Voyager Pharmaceutical Corp
10. NicOx Provides an Update on the Phase 2a Study for NCX 1000
Conducted With Axcan
11. Indivumed Study Provides Sound Scientific Basis for a Predictive
Drug Test- Platform